Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Archer, PhD
Researcher Associate Professor
Hematology/Oncology/BMT - Sickle Cell
Department of Pediatrics
Emory University School of Medicine
2015 Uppergate Road
Atlanta, Georgia, United States
David Archer is a pediatric hematologis/oncologist at Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta. He is also engaged with Emory University School of medicine as associate professor (Hematology/Oncology/BMT – Sickle cell) in department of pediatrics. His research interests are focused on the pathogenesis of sickle cell disease in respect to the generation, prevention and treatment of organ dysfunction. His recent studies on the pathogenesis of sickle cell nephropathy are likely to examine the role of endothelial cells in the generation of both the proteinuria and the concentrating defects associated with renal dysfunction. In particular his lab employs hematopoietic stem cell transplantation to correct the hematological defect in murine models of sickle cell disease.
Dr. Archer and his lab have considerable experience in the maintenance of sickle mouse colonies, transplantation, hematological and functional analysis of the outcomes. He has many published research articles to his credit by working on animal models of sickle cell disease and its complications.
Representative Publications:
Nonhematopoietic Nrf2 dominantly impedes adult progression of sickle cell anemia in mice
Body composition and grip strength are improved in transgenic sickle mice fed a high-protein diet
Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease
The glomerulopathy of sickle cell disease
Related Content
-
Tamara Nicole New, MDTamara Nicole New, MD works as Assistant...
-
A Genome-Wide Association Study Identifies Blood Disorder–Related Variants Influencing Hemoglobin A1c With Implica...OBJECTIVE We aimed to identify hemoglobi...
-
Pediatric to Adult Transition in Sickle Cell Disease: Survey Results From Young Adult PatientsBackground/Aims: We surveyed sickle cel...
-
Clayton Andrews, LAPCClayton Andrews is a 35-year-old patient...
-
6th Annual Chicago Sickle Cell SummitDate & Time Sep 28, 2023 11:00 AM...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
Gene-Therapy Company Crispr Drops as FDA Puts Trial on HoldCrispr Therapeutics AG plunged after the...